Skip to main content
OpenTrials
Completed

NCT Number: NCT00740870

Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort

The primary objective is to confirm the long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. The secondary objectives are to evaluate long-term functionality at 10 years and to assess safety, procedural success, and clinical utility of transcatheter implantation of the Melody TPV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Congenital Heart Defects Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dysfunctional Right Ventricular Outflow Tract Conduits Heart Defects, Congenital Heart Diseases

Age range

5 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nicklaus Children's Hospital, Miami, Florida, United States

Loading trial locations.

About this study

The primary objective is to confirm the long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. The secondary objectives is to evaluate long-term functionality at 10 years and to assess safety, procedural success, and clinical utility of transcatheter implantation of the Melody TPV.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than or equal to 5 years of age
  • Weight greater than or equal to 30 kilograms
  • Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted, or a stented bioprosthesis with a rigid circumferential sewing ring in the RVOT that has an internal diameter greater than or equal to 18 mm and less than or equal to 22 mm when originally implanted.
  • Any of the following by transthoracic echocardiography:
  • For patients in New York Heart Association (NYHA) Classification II, III, or IV: Moderate (3+) or severe (4+) pulmonary regurgitation AND/OR Mean RVOT gradient greater than or equal to 35 mmHg
  • For patients in NYHA Classification I:Severe (4+) pulmonary regurgitation with RV dilatation or dysfunction AND/OR Mean RVOT gradient greater or equal to 40 mmHg

Exclusion criteria

  • Active endocarditis
  • Major or progressive non-cardiac disease (liver failure, renal failure, cancer)that has a life expectancy of less than one year
  • Patient or guardian unwilling or unable to provide written informed consent or comply with follow-up requirements
  • Obstruction of the central veins (including the superior and inferior vena cava, bilateral iliac veins) such that the delivery system cannot be advanced to the heart via transvenous approach from either femoral vein or internal jugular vein
  • Positive urine or serum pregnancy test 24 hours prior to procedure in female patients of child bearing potential
  • Known intravenous drug abuse

Treatment and study plan

Transcatheter Pulmonary Valve replacement

Device

Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.

Other names: Melody Transcatheter Pulmonary Valve

Primary outcomes

  1. Kaplan-Meier Freedom From TPV Dysfunction

    Time frame: 5 years

    To assess whether long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. This study is designed to test the null hypothesis that the true freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is less than or equal to 36% (PControl). To reject the null hypothesis means that freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is greater than 36% (PControl). The null (H0) and alternative (HA) hypotheses are written as follows:H0: PMelody ≤ PControl and HA: PMelody > PControl. TPV dysfunction is a composite outcome defined as the following:

    • Hemodynamic dysfunction of the TPV
    • Moderate or greater pulmonary regurgitation, and/or
    • Mean Right Ventricular Outflow Tract (RVOT) gradient greater than 40 mmHg
    • RVOT reoperation for conduit dysfunction or device-related reasons
    • Catheter re-intervention on the TPV

Secondary outcomes

  1. Freedom From TPV Dysfunction at 10 Years

    Time frame: 10 years

    The outcome measure for this objective is TPV dysfunction, which is a composite outcome defined as RVOT reoperation for conduit dysfunction or device-related reasons, catheter re-intervention on the TPV, or hemodynamic dysfunction of the TPV (moderate or greater pulmonary regurgitation, and/or a mean RVOT gradient greater than 40 mmHg).

  2. Procedural Success

    Time frame: Within 24 Hours post implant

    Procedural success is a composite outcome defined as:

    • Melody TPV fixated within the desired location
    • Right Ventricle (RV) - Pulmonary Artery (PA) peak-to-peak gradient (measured in the catheterization lab) less than 35 mmHg post-implant
    • Less than mild pulmonary regurgitation by angiography post-implant
    • Free of explant at 24 hours post-implant

  3. Serious Procedural Adverse Event (AE)

    Time frame: 5 years

    A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).

  4. Serious Procedural Adverse Event (AE)

    Time frame: 10 years

    A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).

  5. Serious Device-related Adverse Event

    Time frame: 5 years

    A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).

  6. Serious Device-related Adverse Event

    Time frame: 10 years

    A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).

  7. Kaplan-Meier Freedom From Major Stent Fracture at 5 Years

    Time frame: 5 years

    Major stent fracture is defined as a stent fracture requiring intervention to prevent permanent impairment of a body function or permanent damage to a body structure.

  8. Kaplan-Meier Freedom From Major Stent Fracture at 10 Years

    Time frame: 10 years

    Major stent fracture is defined as a stent fracture requiring intervention to prevent permanent impairment of a body function or permanent damage to a body structure.

  9. Kaplan-Meier Freedom From Catheter Re-intervention on TPV

    Time frame: 5 years

    Catheter Re-intervention is defined as: any catheter-based intervention involving the TPV, including balloon dilatation, stenting, or placement of a second TPV

  10. Kaplan-Meier Freedom From Catheter Re-intervention on TPV

    Time frame: 10 years

    Catheter Re-intervention is defined as: any catheter-based intervention involving the TPV, including balloon dilatation, stenting, or placement of a second TPV

  11. Kaplan-Meier Freedom From Surgical Replacement of the RVOT Conduit

    Time frame: 5 years

    Surgical Replacement of the RVOT Conduit is defined as any surgical procedure to repair, alter, or explant the TPV

  12. Kaplan-Meier Freedom From Surgical Replacement of the RVOT Conduit

    Time frame: 10 years

    Surgical Replacement of the RVOT Conduit is defined as any surgical procedure to repair, alter, or explant the TPV

  13. Kaplan-Meier Freedom From Death (All-cause, Procedural and Device-related)

    Time frame: 5 years

    Deaths is defined as all-cause, procedural and device-related events at 5 years

  14. Kaplan-Meier Freedom From Death (All-cause, Procedural and Device-related)

    Time frame: 10 years

    Deaths is defined as all-cause, procedural and device-related events at 10 years

  15. Functional Assessment (NYHA Classification)

    Time frame: 6 Months

    Improvement in Functional Assessment (NYHA Classification) at 6 months post implant.

Sponsors and collaborators

Lead sponsor

Medtronic Cardiovascular

Industry

Registry information

Official study title

Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Feasibility Study

Important dates

Study start
2007
Primary completion
2015
Study completion
2020
First posted
Aug 25, 2008
Registry last updated
Mar 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.